title: Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma.
authors.affiliation: Royal Marsden NHS Foundation Trust, Fulham Road, London, SW3 6JJ, UK.
authors.forename: Lavinia
authors.initials: L
authors.lastname: Spain
authors.affiliation: Royal Marsden NHS Foundation Trust, Fulham Road, London, SW3 6JJ, UK.
authors.forename: James
authors.initials: J
authors.lastname: Larkin
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D060890:B7-H1 Antigen / Q000276:immunology; D060908:CTLA-4 Antigen / Q000276:immunology; D002986:Clinical Trials as Topic; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D000074324:Ipilimumab / Q000627:therapeutic use*; D008545:Melanoma / Q000188:drug therapy* / Q000401:mortality; D000077594:Nivolumab; D061026:Programmed Cell Death 1 Receptor / Q000276:immunology; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D060890:B7-H1 Antigen; D060908:CTLA-4 Antigen; D000074324:Ipilimumab; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D000077594:Nivolumab; C582435:pembrolizumab
keywords: ipilimumab; melanoma; nivolumab; pembrolizumab; survival; toxicity